Table 2. Summary of SARS-CoV-2 Oral Antivirals Currently Authorized for Use in Mild to Moderate COVID-19

	Paxlovid	Molnupiravir
Date FDA EUA Issued	12/22/21	12/23/21
Criteria	• High-risk adults and children ≥12 years of age and weighing ≥40 kg, **and** • with laboratory-confirmed SARS-CoV-2, **and** • who are within 5 days of symptom onset, **and** • who are at high risk for progression to severe COVID-19	• High risk individuals ≥18 years of age, **and** • with laboratory-confirmed SARS-CoV-2, **and** • who are within 5 days of symptom onset, **and** • who are at high risk for progression to severe COVID-19, **and** • for whom alternative, FDA-authorized COVID-19 treatment options are not accessible or clinically appropriate
Formulation	Nirmatrelvir 150 mg tablets, ritonavir 100 mg tablet	Molnupiravir 200 mg capsules
Dosage	Nirmatrelvir 300 mg (2 tablets) + ritonavir 100 mg BID (1 tablet) with a fatty food/meal; do not crush the tablets In patients with moderate renal impairment (eGFR 30-60 mL/min), dosage reduction is required: 1 nirmatrelvir 150-mg tablet with 1 ritonavir 100-mg tablet, taken together twice daily for 5 days Paxlovid is not recommended in patients with severe renal impairment (eGFR <30 mL/min)	Molnupiravir 800 mg (4 capsules) every 12 hours with or without food; do not open/crush the capsules
Duration	5 days	5 days
Health Care Provider Fact Sheet	www.fda.gov/media/155050/download	https://www.fda.gov/media/155054/download
Patient/Family Fact Sheet, English and Spanish	https://www.fda.gov/media/155051/download https://www.fda.gov/media/155075/download	https://www.fda.gov/media/155055/download https://www.fda.gov/media/155115/download